Randomized Phase II Study of Panitumumab Rechallenge Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-type Chemorefractory Mestastatic Colorectal Cancer Patients
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Panitumumab (Primary) ; Regorafenib (Primary)
- Indications Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms PARERE
- 24 Nov 2023 Planned End Date changed from 15 Jun 2024 to 15 Jun 2025.
- 24 Nov 2023 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 13 Sep 2022 Initial results (n=101) presented at the 47th European Society for Medical Oncology Congress.